You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Send a link to this page to your friends and colleagues.
Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve 155 British patients with type 2 diabetes. The test on human subjects, although very early-stage, puts the company in the lead to develop an oral form of a GLP-1 drug.
GLP-1-glucagon-like peptide-is a delicate gut hormone whose beneficial effects on the digestive system have made it one of the most promising diabetes therapies in modern times. Those effects include:
Novo's version of GLP-1, Victoza, like all other GLP-1s on the market, must be taken by injection. The relative fragility of the protein-based drug, which gives it a "half life" of two minutes once it circulates in the body, requires the direct application that only injections can give.
(GLP-1 analogs like exenatide and liraglutide must also be taken by injection.)
If Novo can create an effective version of Victoza in pill form, the marketing advantages would be formidable. Most type 2 patients who are taking GLP-1 drugs, if given a choice between daily injections and pills, would opt for pills. But Novo still has to overcome the biggest challenge in developing an oral diabetes medication: how to get the fragile molecules in the drug through the acid baths of the digestive system to the point where they can enter the bloodstream.
Novo is banking on Eligen®, a drug delivery technology developed by one of its research partners, Emisphere Technologies in New Jersey. Eligen® facilitates the very rapid absorption of molecules across cell membranes in the gut and into the bloodstream-crucial to preserving their viability.
The test with British subjects is expected to yield first results by 2011.
* * *
0 comments - Feb 1, 2010
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.